How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,853 results for

Pet Safety

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Positron emission tomography (PET) scans for lymphoma - re-review

Positron emission tomography (PET) scans for lymphoma - re-review Final Positron Emission Tomography (PET) scans for lymphoma – re-review: findings and decision Page 1 of 3 Health Technology Clinical Committee Findings and Decision Topic: Positron Emission Tomography (PET) scans for lymphoma – re-review Meeting date: November 16, 2018 Final adoption: January 18, 2019 Meeting materials and transcript are available on the HTA website. Number and coverage topic: 20181116B – Positron Emission (...) and Industries 1-800-547-8367 Public Employees Health Plan 1-800-200-1004 Washington State Medicaid 1-800-562-3022 WA - Health Technology Assessment November 16, 2018 Final Positron Emission Tomography (PET) scans for lymphoma – re-review: findings and decision Page 2 of 3 TCC coverage vote and formal action: Committee decision Based on the deliberations of key health outcomes the committee decided that it had the most complete information: a comprehensive and current evidence report, public comments

2018 Washington Health Care Authority

2. 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for oncological indications

18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for oncological indications '); } else { document.write(' '); } ACE | 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for oncological indications Search > > 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for oncological indications - 18F-fluorodeoxyglucose positron emission tomography with computed tomography(FDG-PET-CT (...) ) for oncological indications Published on 1 October 2018 Guidance Recommendations The Ministry of Health’s MTAC has recommended 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for the management of the following oncological indications: All subtypes of the following tumours: Cervical cancer Colorectal cancer Non-small cell lung cancer Solitary pulmonary nodule Hodgkin’s disease (lymphoma) Non-Hodgkin’s disease (lymphoma) Melanoma Myeloma Oesophageal and oesophago

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

3. F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer

F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer 1 Public Summary Document Application No. 1357.1 – F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer Applicant: Australasian Association of Nuclear Medicine Specialists (AANMS) Date of MSAC consideration: MSAC 74th Meeting, 22-23 November 2018 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC (...) website 1. Purpose of application An application requesting Medicare Benefit Schedule (MBS) listing of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer in patients who have locally advanced disease where other imaging does not provide sufficient information to determine appropriate treatment (population 1) and in patients in whom recurrent or metastatic disease is suspected and for whom active therapy is likely to be pursued (population 2

2018 Medical Services Advisory Committee

4. EANM-EAN recommendations for the use of brain 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus Full Text available with Trip Pro

EANM-EAN recommendations for the use of brain 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus - Nobili - 2018 - European Journal of Neurology - Wiley Online Library Search (...) within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. EAN Guidelines/CME Article Free Access European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus Corresponding Author E-mail address: Department of Neuroscience (DINOGMI), University of Genoa

2018 European Academy of Neurology

5. Positron Emission Tomography (PET) for Alzheimer disease

? How does PET compare with other techniques? What is the impact of PET on clinical management and health outcomes? Are there any safety issues associated with the use of PET for detection or the prediction of AD development? Have definitive patient selection criteria been established for PET imaging for AD? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Alzheimer Disease; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography (...) Positron Emission Tomography (PET) for Alzheimer disease Positron Emission Tomography (PET) for Alzheimer disease Positron Emission Tomography (PET) for Alzheimer disease HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Positron Emission Tomography (PET) for Alzheimer disease. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors

2017 Health Technology Assessment (HTA) Database.

6. Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning

studies (100). Please remove one or more studies before adding more. Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03130036 Recruitment Status : Completed First Posted : April 26, 2017 Last (...) Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

7. F-18 Flurodeoxyglucose Positron Emission Tomography (FDG PET) for the diagnosis of Alzheimer's Disease

F-18 Flurodeoxyglucose Positron Emission Tomography (FDG PET) for the diagnosis of Alzheimer's Disease Appl tom Applic Date o Context at www 1. In Septe Nuclear Victoria fluorod (AD) w 2. After co and cos PET) fo inconclu effectiv weak cl health o MSAC ? ana Dep sam ? am ana pop serv ? a co MSAC lication N mography cant: of MSAC c t for decisio w.msac.gov. Purpose o ember 2013 r Medicine a, requestin eoxyglucos where other d MSAC’s a onsidering t st-effectiven or the diagn usive, MSA veness (...) and outcomes were discounted at an annual rate of 5%, in accordance with MSAC Guidelines. Table 3 presents the base case results in terms of the QALY gain offered by FDG PET. Table 3 Incremental cost-effectiveness ratio of FDG PET versus SPECT Parameter FDG PET arm SPECT arm Incremental Cost $98,242 $99,585 -$1160 QALY 2.41 2.39 0.03 Incremental cost per QALY - - -$42,991 Abbreviations: FDG PET, fluorodeoxyglucose positron emission tomography; QALY, quality-adjusted life year; SPECT, single-photon emission

2015 Medical Services Advisory Committee

8. Substitution of 68Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369

to comparative safety, clinical effectiveness and cost-effectiveness, MSAC supported substitution of 68 Gallium-1,4,7,10-tetra azacyclododecane-1,4,7,10-tetraacetic acid-peptide ( 68 Ga-DOTA-peptide) positron emission tomography (PET)/ computed tomography (CT) scanning in lieu of radioactive indium-labelled octreotide ( 111 In-octreotide) single-photon emission computed tomography (SPECT)/ CT for the diagnosis of gastroenteropancreatic neuroendocrine tumours (GEP NETs). MSAC accepted that in contrast to 111 (...) Substitution of 68Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369 1 Minutes from MSAC 69th Meeting, 6-7 April 2017 Application No. 1479R – Substitution of 68 Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369 MSAC’s advice to the Minister After considering the strength of the available evidence in relation

2018 Medical Services Advisory Committee

9. Positron Emission Tomography (PET) for Alzheimer disease

Positron Emission Tomography (PET) for Alzheimer disease Positron Emission Tomography (PET) for Alzheimer disease Positron Emission Tomography (PET) for Alzheimer disease HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Positron Emission Tomography (PET) for Alzheimer disease. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors (...) ' conclusions Purpose of Technology: Positron emission tomography (PET) is a 3-dimensional (3D) nuclear imaging technique that measures the level of physiologic and biochemical activity or other organic function in an organ or tissue by reflecting the distribution of a radiotracer that has been administered to the patient. PET has been proposed as a method for diagnosing and predicting development of Alzheimer disease (AD). Relevant Questions: Is PET an accurate diagnostic test for detection or prediction

2016 Health Technology Assessment (HTA) Database.

10. F-18 Fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer's disease

diagnosis and the pathological process that leads to the dementia of Alzheimer's disease begins a decade or more before diagnosis. Authors' conclusions After considering the available evidence presented in relation to safety, clinical effectiveness and cost-effectiveness of F-18 fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer's disease where other diagnostic methods are inconclusive, MSAC did not support the public funding because of uncertain cost effectiveness (...) F-18 Fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer's disease F-18 Fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer's disease F-18 Fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer's disease Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made

2015 Health Technology Assessment (HTA) Database.

11. F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer

F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer 1 Public Summary Document Application No. 1357 – F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer Applicant: Australian Association of Nuclear Medicine Date of MSAC consideration: MSAC 62 nd Meeting, 26- 28 November 2014 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, see at www.msac.gov.au 1. Purpose (...) of application and links to other applications An application requesting Medicare Benefits Schedule (MBS) listing of F-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) for the evaluation and staging of spread of disease in proven locally advanced breast cancer (LABC), suspected locally and regionally recurrent, or suspected metastatic breast cancer was received from the Australasian Association of Nuclear Medicine Specialists by the Department of Health in May 2013. The purpose

2014 Medical Services Advisory Committee

12. A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JN

-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03693391 Recruitment Status : Completed First Posted : October 3, 2018 Last Update Posted (...) for Volume of Distribution (V[t]) of 18FJNJ-64511070 [ Time Frame: Approximately up to 1 hour on Day 2 ] The distribution of [18F]JNJ-64511070 in brain will be measured by positron emission tomography (PET) scans obtained along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics and volume of distribution (V[t]) of [18F]JNJ-64511070. Percentage of Alpha-amino-3-hydroxy-5-methyl-4

2018 Clinical Trials

13. Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal (...) Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2018 Clinical Trials

14. Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Pancreatic Cancer

number of saved studies (100). Please remove one or more studies before adding more. Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Pancreatic Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details (...) stable disease following ≥16 weeks of treatment with platinum-based chemotherapy and (2) who have signed consent to participate in a clinical trial that contains PARP inhibitor therapy and are anticipated to receive this treatment or (3) will receive PARP inhibitor therapy as part of their clinical care. A pre-treatment 18F-FluorThanatrace ([18F]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to the start of treatment with a PARP inhibitor. PET/CT imaging

2018 Clinical Trials

15. Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors

registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors (GLIROPA) The safety and scientific validity of this study is the responsibility (...) Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2018 Clinical Trials

16. Microglial Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714

remove one or more studies before adding more. Microglial Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714 (NARCOGLIE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03754348 (...) Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714 Estimated Study Start Date : November 27, 2018 Estimated Primary Completion Date : November 2020 Estimated Study Completion Date : January 2021 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Experimental group hypothalamus neuroinflammation evaluation Radiation: PET scan with tracer injection [18F] DPA-714

2018 Clinical Trials

17. Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)

of saved studies (100). Please remove one or more studies before adding more. Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details (...) the scanner for up to 90 minutes Device: Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI) FDA approved scanner Other Names: PET/MR PET/MRI Outcome Measures Go to Primary Outcome Measures : Measure the impact of MR acquisition correction sequences for attenuation correction on PET quantitation accuracy [ Time Frame: At the time of the MRI scan ] -PET images from PET/MRI with the MR derived attenuation correction will be compared to images generated with the CT attenuation correction from

2018 Clinical Trials

18. A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739

the maximum number of saved studies (100). Please remove one or more studies before adding more. A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03437590 Recruitment Status : Completed (...) Using [18F]-JNJ-64413739 Actual Study Start Date : March 15, 2018 Actual Primary Completion Date : October 19, 2018 Actual Study Completion Date : October 19, 2018 Arms and Interventions Go to Arm Intervention/treatment Experimental: Part 1: JNJ-55308942 and [18F]-JNJ-64413739 Participants will first undergo a baseline positron emission tomography (PET)/ magnetic resonance (MR) scan with [18F]-JNJ-64413739 on Day 1. In Period 1 (on Day 2) and Period 2 (on Day 1), participants will receive oral dose

2018 Clinical Trials

19. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. Full Text available with Trip Pro

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. Amyloid positron emission tomography (PET) detects amyloid plaques in the brain, a core neuropathological feature of Alzheimer disease.To determine if amyloid PET is associated with subsequent changes in the management of patients with mild cognitive impairment (MCI) or dementia of uncertain etiology.The Imaging Dementia (...) -Evidence for Amyloid Scanning (IDEAS) study was a single-group, multisite longitudinal study that assessed the association between amyloid PET and subsequent changes in clinical management for Medicare beneficiaries with MCI or dementia. Participants were required to meet published appropriate use criteria stating that etiology of cognitive impairment was unknown, Alzheimer disease was a diagnostic consideration, and knowledge of PET results was expected to change diagnosis and management. A total

2019 JAMA

20. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Full Text available with Trip Pro

of three positron emission tomography (PET) scans: baseline, Day 1 (~ 30 min post-dosing) and Day 2 (~ 24 h post-dosing), using a radiolabelled αvβ6-specific ligand, [18F]FB-A20FMDV2. The primary endpoint was whole lung volume of distribution (VT), not corrected for air volume, at ~ 30 min post-dose compared with pre-dose. The study success criterion, determined using Bayesian analysis, was a posterior probability (true % reduction in VT > 0%) of ≥80%.Eight participants with IPF were enrolled and seven (...) A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with poor prognosis and a significant unmet medical need. This study evaluated the safety, pharmacokinetics (PK) and target engagement in the lungs, of GSK3008348, a novel inhaled alpha-v beta-6 (αvβ6) integrin inhibitor

2020 Respiratory research

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>